Antihelminthic Agents

Benzimidazoles bind selectively to beta-tubulin in helminth cells at the colchicine-binding site, preventing tubulin polymerization into microtubules. Microtubules are essential for mitotic spindle formation, intracellular transport, and glucose uptake. Loss of microtubule function depletes glycogen stores, causes adenosine triphosphate (ATP) depletion, and ultimately kills the worm. The drugs are active against eggs, larvae, and adult worms — a breadth that is relevant to both treatment and transmission interruption.

Mebendazole is minimally absorbed from the gastrointestinal tract, with very low systemic bioavailability under fasting conditions. This poor absorption is pharmacologically advantageous for intestinal nematode infections, where high luminal drug concentrations are desired without systemic exposure. It is effective against Ascaris lumbricoides, Trichuris trichiura, Enterobius vermicularis, and hookworm species. Because systemic absorption is so limited, mebendazole has no utility for tissue-invasive helminthiasis.

Albendazole is a prodrug that undergoes hepatic oxidation to its active sulfoxide metabolite. This metabolite achieves substantially higher systemic concentrations than the parent compound. Fat co-administration markedly increases absorption, making co-administration with food mandatory for systemic indications. Albendazole distributes widely into tissues including cyst fluid and cerebrospinal fluid, making it the benzimidazole of choice for tissue-invasive disease including neurocysticercosis and echinococcosis. For intestinal nematodes, a single dose of albendazole is the World Health Organization (WHO)-preferred agent for mass drug administration programs.

For neurocysticercosis — caused by larval Taenia solium cysts in the central nervous system — albendazole is the primary antiparasitic agent. It must always be combined with corticosteroids to manage the inflammatory response triggered by dying cysts, which can otherwise cause seizures or cerebral edema. Antiepileptic drugs are added when seizures are present. For echinococcosis (hydatid disease) caused by Echinococcus granulosus, albendazole is used as perioperative adjunctive therapy with surgical or radiological cyst management, reducing the risk of seeding from cyst rupture.

At the single doses used for intestinal nematode mass drug administration, both benzimidazoles are exceptionally well tolerated. At the prolonged higher doses required for tissue-invasive disease, albendazole carries risk of hepatotoxicity and bone marrow suppression, requiring liver function and blood count monitoring during treatment cycles. Both agents are teratogenic in animal studies and are avoided in the first trimester; the WHO accepts single-dose use from the second trimester for intestinal helminthiasis in high-prevalence settings where the benefit of treatment outweighs risk.

Ivermectin binds selectively to glutamate-gated chloride ion channels (GluCl channels) present in invertebrate nerve and muscle cells. Binding causes irreversible channel opening, increasing chloride ion permeability, hyperpolarizing the cell membrane, and producing flaccid paralysis and death of the organism. GluCl channels are absent in mammalian central nervous system cells. Under normal circumstances ivermectin also does not penetrate the mammalian blood-brain barrier because it is a substrate for the P-glycoprotein efflux pump encoded by the multidrug resistance 1 (MDR1) gene, which actively exports it from the central nervous system. In animals or rare humans with loss-of-function MDR1 mutations, or when P-glycoprotein inhibitors (such as ritonavir or verapamil) are co-administered, ivermectin can penetrate the central nervous system and cause neurotoxicity.

Ivermectin is the drug of choice for strongyloidiasis caused by Strongyloides stercoralis. In immunocompromised patients, Strongyloides can cause hyperinfection syndrome — massive autoinfection with filariform larvae crossing the gut wall, carrying enteric bacteria and causing gram-negative septicemia — which is fatal if untreated. Ivermectin is given until consecutive negative stool examinations confirm eradication in immunocompromised patients. Screening and empirical treatment for Strongyloides before starting corticosteroids or other immunosuppressive therapy is a critical safety practice in patients from endemic regions.

For onchocerciasis (river blindness) caused by Onchocerca volvulus, ivermectin is microfilaricidal — it kills the larval microfilariae but does not reliably kill adult worms at standard doses. Annual or semi-annual community-based mass treatment is the basis of the WHO African Programme for Onchocerciasis Control. For lymphatic filariasis caused by Wuchereria bancrofti or Brugia species, ivermectin combined with albendazole is the mass drug administration regimen used where onchocerciasis is co-endemic.

In regions of Central Africa where Loa loa (African eye worm) is co-endemic with onchocerciasis, ivermectin administration carries a risk of fatal encephalopathy in individuals with very high Loa loa microfilarial densities. Rapid destruction of Loa loa microfilariae in central nervous system vessels causes a severe inflammatory encephalopathy. Pre-treatment assessment of Loa loa microfilarial burden is mandatory before ivermectin use in co-endemic regions. This constraint is operationally significant for mass drug administration programs in parts of Cameroon, the Democratic Republic of Congo, and neighboring countries.

Praziquantel acts through two complementary mechanisms. At low concentrations it increases calcium permeability of the parasite tegument, causing muscular contraction and spastic paralysis of the worm. At higher concentrations it causes severe vacuolization and physical disintegration of the tegument, exposing cryptic antigens that are normally hidden from host immune recognition. Exposure of these antigens enables host immune effector mechanisms — antibody-dependent cellular cytotoxicity, complement — to attack and kill the worm. The dual mechanism of rapid paralysis followed by immune-mediated destruction accounts for praziquantel's lethal efficacy against adult worms.

Praziquantel is the treatment of choice for all Schistosoma species, including Schistosoma mansoni, Schistosoma haematobium, and Schistosoma japonicum. Cure rates exceed 85 percent for most species with a single treatment course. Because praziquantel has limited activity against immature schistosomula, a second course given several weeks after the first substantially improves cure rates by catching maturing worms that were not susceptible at the time of initial treatment. Praziquantel is also first-line for opisthorchiasis (Opisthorchis viverrini, Opisthorchis felineus), clonorchiasis (Clonorchis sinensis), and paragonimiasis (Paragonimus westermani).

The critical exception is fascioliasis caused by Fasciola hepatica or Fasciola gigantica: the Fasciola tegument is inherently resistant to praziquantel, and the drug is ineffective against this fluke. Triclabendazole is the treatment of choice for fascioliasis and should not be substituted with praziquantel.

Praziquantel is effective against intestinal tapeworms including Taenia saginata (beef tapeworm), Taenia solium (pork tapeworm), and Diphyllobothrium latum (fish tapeworm). For neurocysticercosis, praziquantel is an alternative to albendazole, though albendazole is generally preferred because corticosteroids — mandatory co-treatment in neurocysticercosis — reduce praziquantel cerebrospinal fluid penetration by approximately half, while albendazole penetration is not similarly affected. When the combination of albendazole plus praziquantel is used for neurocysticercosis with multiple viable cysts, praziquantel augments rather than replaces albendazole.

Praziquantel is extensively metabolized by cytochrome P450 3A4 (CYP3A4). Rifampicin, a potent CYP3A4 inducer, dramatically reduces praziquantel plasma levels and must not be co-administered during schistosomiasis treatment. Corticosteroids also reduce praziquantel plasma concentrations, which is clinically relevant when both are used together in neurocysticercosis.

Pyrantel is a depolarizing neuromuscular blocking agent that acts as a nicotinic acetylcholine receptor (nAChR) agonist at helminth neuromuscular junctions. Persistent depolarization causes spastic paralysis and expulsion of the worm by normal intestinal peristalsis. Like mebendazole, pyrantel is poorly absorbed from the gastrointestinal tract, confining its activity to the intestinal lumen. It is active against Ascaris lumbricoides, hookworm species, and Enterobius vermicularis but has no activity against Trichuris trichiura, tapeworms, or tissue-invasive helminths. Pyrantel is considered safe in pregnancy given its minimal systemic absorption. It should not be combined with piperazine, which acts by gamma-aminobutyric acid (GABA)-mediated hyperpolarization producing flaccid paralysis — the opposing mechanisms (spastic versus flaccid paralysis) are pharmacologically antagonistic.

Diethylcarbamazine acts by exposing microfilarial surface antigens that are normally masked from host immune recognition, enabling host immune effector mechanisms to destroy the microfilariae. It is predominantly microfilaricidal rather than active against adult worms. Diethylcarbamazine is the drug of choice for lymphatic filariasis when onchocerciasis is not co-endemic (where its use would cause severe Mazzotti reactions from dying Onchocerca volvulus microfilariae), for loiasis at low Loa loa microfilarial burden, and for tropical pulmonary eosinophilia. It is also used as prophylaxis for loiasis in residents of co-endemic regions.

The most clinically significant adverse effects of diethylcarbamazine are not direct drug toxicity but parasite-death reactions: fever, headache, arthralgia, urticaria, and lymphangitis from dying microfilariae. In patients with high Loa loa microfilarial burdens, diethylcarbamazine, like ivermectin, risks fatal encephalopathy and is contraindicated. Diethylcarbamazine is contraindicated in pregnancy.

Resistance to benzimidazoles in helminths is mediated primarily by single-nucleotide polymorphisms in the beta-tubulin gene that alter the colchicine-binding site and reduce drug binding affinity without substantially impairing tubulin function. These mutations are now present in trichostrongylid nematodes of livestock on all inhabited continents. Surveillance for reduced post-treatment cure rates in human soil-transmitted helminthiasis programs, and molecular monitoring for beta-tubulin polymorphisms, are active priorities to detect emerging resistance before it becomes clinically significant.

Sub-optimal microfilarial suppression after observed ivermectin treatment has been documented in Onchocerca volvulus in foci in West Africa, suggesting emerging reduced ivermectin susceptibility. Mechanisms include glutamate-gated chloride channel subunit mutations and upregulation of P-glycoprotein efflux. The development of macrofilaricidal agents — capable of killing adult worms rather than only microfilariae — is an active research priority to address this vulnerability.

Peripheral blood eosinophilia in a patient from a helminth-endemic region should prompt systematic helminth evaluation before initiation of immunosuppressive therapy. Tissue-invasive helminths — Strongyloides, Toxocara, filarial species, Trichinella — drive peripheral blood eosinophilia as a characteristic host response to the presence of helminth larvae in tissue. Corticosteroids administered to a patient with unrecognized Strongyloides stercoralis infection can precipitate hyperinfection syndrome with near-universal fatality. Serological testing for Strongyloides and empirical ivermectin treatment before immunosuppression is a standard safety practice in transplant, oncology, and rheumatology programs.

Neurocysticercosis management is governed by cyst viability. Viable parenchymal cysts and enhancing lesions benefit from antiparasitic therapy with albendazole (with or without praziquantel for multiple cysts) plus mandatory corticosteroids plus antiepileptic drugs if seizures are present. Purely calcified cysts are already dead — antiparasitic treatment provides no benefit and risks triggering inflammation around the calcification. Ventricular and subarachnoid neurocysticercosis require specialized neurosurgical co-management.

For cystic echinococcosis caused by Echinococcus granulosus, albendazole is used as perioperative cover for surgical or percutaneous aspiration procedures (puncture-aspiration-injection-reaspiration, or PAIR), reducing the risk of secondary seeding if cyst contents spill. For alveolar echinococcosis caused by Echinococcus multilocularis, which behaves more like an invasive malignancy, indefinite albendazole suppression is required for medically inoperable disease.